These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15628829)

  • 21. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
    Vinik AI; Zhang Q
    Diabetes Care; 2007 Apr; 30(4):795-800. PubMed ID: 17259481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
    Hollenberg NK
    Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose rosiglitazone in patients with type 2 diabetes mellitus requiring insulin therapy.
    Lopez CA; Kanna B
    Arch Intern Med; 2008 Mar; 168(5):548. PubMed ID: 18332304
    [No Abstract]   [Full Text] [Related]  

  • 25. Pioglitazone is a valid alternative to rosiglitazone.
    Derosa G
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
    Karter AJ; Ahmed AT; Liu J; Moffet HH; Parker MM
    Diabet Med; 2005 Aug; 22(8):986-93. PubMed ID: 16026362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone and delayed onset of proliferative diabetic retinopathy.
    Shen LQ; Child A; Weber GM; Folkman J; Aiello LP
    Arch Ophthalmol; 2008 Jun; 126(6):793-9. PubMed ID: 18541841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Pagkalos EM; Hitoglou-Makedou AD; Pliakos CI; Kazakos KA; Yovos JG; Zebekakis PE; Tziolas IM; Tourkantonis AN
    J Hypertens; 2004 Sep; 22(9):1769-77. PubMed ID: 15311106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosiglitazone prior authorization safety policy: a cohort study.
    Starner CI; Fenrick B; Coleman J; Wickersham P; Gleason PP
    J Manag Care Pharm; 2012 Apr; 18(3):225-33. PubMed ID: 22468731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rosiglitazone decision process at FDA and EMA. What should we learn?
    Pouwels KB; van Grootheest K
    Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes.
    Ovalle F; Bell DS
    Diabetes Care; 2004 Nov; 27(11):2585-9. PubMed ID: 15504990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
    Thayer S; Arondekar B; Harley C; Darkow TE
    Ann Pharmacother; 2010 May; 44(5):791-9. PubMed ID: 20371759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
    Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
    Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of insulin plus rosiglitazone or metformin on serum N-terminal pro-brain natriuretic peptide in type 2 diabetes mellitus: a randomized-controlled study].
    Hu M; Tian H; Zhou X; Wu W; Luo Y; Zhang H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Jun; 25(3):682-5. PubMed ID: 18693456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.